Ocuphire Pharma Inc Gets NDA Approval From FDA For RYZUMVI Type 3 - New Dosage Form
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma Inc has received New Drug Application (NDA) approval from the FDA for RYZUMVI Type 3, a new dosage form of the drug.
September 26, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocuphire Pharma Inc's stock may see positive movement following the FDA approval of RYZUMVI Type 3's new dosage form.
FDA approval is a significant milestone for pharmaceutical companies. It opens up market opportunities and can lead to increased sales and revenues. This news is highly relevant to Ocuphire Pharma Inc and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100